Targeting polo-like kinases: A promising therapeutic approac for cancer treatment

Xiaoqi Liu

doi:10.1016/j.tranon.2015.03.010

Targeting polo-like kinases: A promising therapeutic approac for cancer treatment

Xiaoqi Liu

Producción científica: Review article › revisión exhaustiva

167 Citas (Scopus)

Resumen

Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies.

Idioma original	English
Páginas (desde-hasta)	185-195
Número de páginas	11
Publicación	Translational Oncology
Volumen	8
N.º	3
DOI	https://doi.org/10.1016/j.tranon.2015.03.010
Estado	Published - 2015

Nota bibliográfica

Publisher Copyright:
© 2015 The Authors. Published by Elsevier Inc.

Financiación

Medical writing assistance, supported financially by Boehringer Ingelheim Pharmaceuticals, Inc, was provided by Katie McClendon of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this review. Boehringer Ingelheim was given the opportunity to review for factual accuracy only. This work was supported by the National Institutes of Health (R01CA157429), the American Cancer Society (RSG-13-073-01-CNE), and the National Science Foundation (1049693-MCB). The author declares no conflicts of interest.

Financiadores	Número del financiador
U.S. Department of Energy Chinese Academy of Sciences Guangzhou Municipal Science and Technology Project Oak Ridge National Laboratory Extreme Science and Engineering Discovery Environment National Science Foundation National Energy Research Scientific Computing Center National Natural Science Foundation of China	1049693-MCB
National Institutes of Health (NIH)	R01CA157429
American Cancer Society-Michigan Cancer Research Fund	RSG-13-073-01-CNE

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Oncology
Cancer Research

Acceder al documento

10.1016/j.tranon.2015.03.010

Otros archivos y enlaces

Citar esto

@article{b6fa0dbe330644308a42e9a7184001bd,

title = "Targeting polo-like kinases: A promising therapeutic approac for cancer treatment",

abstract = "Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies.",

author = "Xiaoqi Liu",

note = "Publisher Copyright: {\textcopyright} 2015 The Authors. Published by Elsevier Inc.",

year = "2015",

doi = "10.1016/j.tranon.2015.03.010",

language = "English",

volume = "8",

pages = "185--195",

number = "3",

}

TY - JOUR

T1 - Targeting polo-like kinases

T2 - A promising therapeutic approac for cancer treatment

AU - Liu, Xiaoqi

PY - 2015

Y1 - 2015

N2 - Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies.

AB - Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies.

UR - https://www.scopus.com/pages/publications/84930745615

UR - https://www.scopus.com/pages/publications/84930745615#tab=citedBy

U2 - 10.1016/j.tranon.2015.03.010

DO - 10.1016/j.tranon.2015.03.010

M3 - Review article

AN - SCOPUS:84930745615

SN - 1944-7124

VL - 8

SP - 185

EP - 195

JO - Translational Oncology

JF - Translational Oncology

IS - 3

ER -

Targeting polo-like kinases: A promising therapeutic approac for cancer treatment

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto